3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Melanoma
50
Carcinoma, Non-Small-Cell Lung
50
Carcinoma, Renal Cell
37
Carcinoma, Hepatocellular
20
Neoplasm Metastasis
19
Lung Neoplasms
19
Neoplasms
17
Squamous Cell Carcinoma of Head and Neck
16
Stomach Neoplasms
15
Colorectal Neoplasms
15
Carcinoma, Transitional Cell
14
Adenocarcinoma Of Esophagus
12
Prostatic Neoplasms
10
Hodgkin Disease
10
Brain Neoplasms
10
Urinary Bladder Neoplasms
8
Ovarian Neoplasms
8
Multiple Myeloma
8
Triple Negative Breast Neoplasms
7
Rectal Neoplasms
7
Pancreatic Neoplasms
7
Esophageal Neoplasms
7
Breast Neoplasms
7
Colonic Neoplasms
6
Clear-cell metastatic renal cell carcinoma
6
Carcinoma, Basal Cell
6
Uveal Melanoma
5
Uterine Cervical Neoplasms
5
Thyroid Neoplasms
5
Sarcoma
5
Interventions
olaparib
3
enzalutamide
2
darolutamide
2
Prednisone
2
Prednisolone
2
Pluvicto
2
Docetaxel
2
Androgen Antagonists
2
Abiraterone Acetate
2
testosterone 17 beta-cypionate
1
radium Ra 223 dichloride
1
fludarabine phosphate
1
fludarabine
1
cabazitaxel
1
alovudine
1
abiraterone
1
Standard of Care
1
Radium-223
1
PSMA-617
1
Nivolumab
1
Gonadotropin-Releasing Hormone
1
Cyclophosphamide
1
Blood Specimen Collection
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Metastatic Castration-resistant Prostate Cancer
×
Nivolumab
×
90 days
×
Clear all
NCT04109729
2026-06-01
Rad2Nivo
University of Utah
Phase 1
Active not recruiting
39 enrolled